Potential Impact of the 70-gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors: a Single Institution Experience

PUBLICATION:
Breast. 2013 Aug;22(4):419-24. doi: 10.1016/j.breast.2013.03.013. Epub 2013 May 3.

AUTHORS:
Torrisi R., Garcia-Etienne C.A., Losurdo A., Morenghi E., Di Tommaso L., Gatzemeier W., Sagona A., Fernandes B., Rossetti C., Eboli M., Rubino A., Barbieri E., Andreoli C., Orefice S., Gandini C., Rota S., Zuradelli M., Masci G., Santoro A., Tinterri C.

SUMMARY:
MammaPrint (MP) results would have led to different treatment decisions in 13/46 (28%) and in 20/68 (29%) pts according to NCCN and St. Gallen recommendations, respectively. Among the 68 ER/PgR positive, HER2 negative tumors, Ki-67 ≥ 20% was the only significant predictor of a high risk-MP.